|
My guess is that we are going to get the HIV and malaria trials started before year-end which is only a few weeks away (taking out the holidays). Because these are world-major diseases there will (should be) enormous media coverage. If Alan Enbring does a good job, perhaps stories will center on VICL's technology. Also, with the recent tragic death at Univ. of Pa. where they used viral vectors, perhaps the "smart" money has taken cognizance of the fact that our company is not using viral vectors and so may be the shortest road to the magic world of gene therapy. Finally, the Allovectin pivotal trials will report this coming summer. That is not that far off. If the news is good (i.e., it looks like the company could file an NDA by the end of the year and get approval in mid-2001, that could send this stock to the moon. Tell me, o believers, how many weak hands now own Vical? I have owned a large position for many years and I am not looking for nickels and dimes. If the institutions want to begin putting together a position, where can they get large blocks of stock without punching up the price. That is what I believe is happening. Some funds are accumulating and are trying not to push the price too high but are determined to get in. I have noticed the stock sometimes drifts during the day but at the end of the day there is substantial buying that pushes up the price. Then, the next day, the same thing happens. I don't blame them for wanting it but they are not getting my shares! Good luck to all long term investors who have had faith in the science and management of this company. |
